Phaseline

Companies › Jabez Bioscience

Jabez Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JBZ-001
DHODH inhibitor
DHODHPhase 1Solid TumorFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06801002JBZ-001Phase 1Solid TumorOncologyFeb 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

DHODH (1)

Companies with the same targets

Immunic Kiora Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.